Performance of factor IX extended half‐life product measurements in external quality control assessment programs

BACKGROUND: Patients with hemophilia B are increasingly treated with extended half‐life (EHL) factor IX (FIX) concentrates. For the laboratory, introduction of these EHL concentrates presents a major challenge. To understand the variation in FIX activity levels, all available diagnostic assays need...

Descripción completa

Detalles Bibliográficos
Autores principales: Nederlof, Angelique, Kitchen, Steve, Meijer, Piet, Cnossen, Marjon, Ali Pour, Nae, Kershaw, Geoffrey, Jennings, Ian, Walker, Isobel, de Maat, Moniek P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496271/
https://www.ncbi.nlm.nih.gov/pubmed/32311825
http://dx.doi.org/10.1111/jth.14847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496271/
https://www.ncbi.nlm.nih.gov/pubmed/32311825
http://dx.doi.org/10.1111/jth.14847

Ejemplares similares